title: Molecular genetic markers for thyroid FNAB. Established assays and future perspective.
abstract: OBJECTIVE
  Thyroid nodules > 1 cm are observed in about 12% of unselected adult employees aged 18-65 years screened by ultrasound scan (40). While intensive ultrasound screening leads to early detection of thyroid diseases, the determination of benign or malignant behaviour remains uncertain and may trigger anxieties in many patients and their physicians. A considerable number of thyroid resections are consecutively performed due to suspicion of malignancy in the detected nodes. Fine needle aspiration biopsy (FNAB) has been recommended for the assessment of thyroid nodules to facilitate detection of thyroid carcinomas but also to rule out malignancy and thereby avoid unnecessary thyroid resections. However, cytology results are dependent on experience of the respective cytologist and unfortunately inconclusive in many cases.
  
  
  METHODS
  Molecular genetic markers are already used nowadays to enhance sensitivity and specificity of FNAB cytology in some centers in Germany. The most clinically relevant molecular genetic markers as pre-operative diagnostic tools and the clinical implications for the intraoperative and postoperative management were reviewed.
  
  
  RESULTS
  Molecular genetic markers predominantly focus on the preoperative detection of thyroid malignancies rather than the exclusion of thyroid carcinomas. While some centers routinely assess FNABs, other centers concentrate on FNABs with cytology results of follicular neoplasia or suspicion of thyroid carcinoma. Predominantly mutations of BRAF, RET/PTC, RAS, and PAX8/PPARγ or expression of miRNAs are analyzed. However, only the detection of BRAF mutations predicts the presence of (papillary) thyroid malignancy with almost 98% probability, indicating necessity of oncologic thyroid resections irrespective of the cytology result. Other genetic alterations are associated with thyroid malignancy with varying frequency and achieve less impact on the clinical management.
  
  
  CONCLUSIONS
  Molecular genetic analysis of FNABs is increasingly performed in Germany. Standardization, quality controls, and validation of various methods need to be implemented in the near future to be able to compare the results. With increasing knowledge about the impact of genetic alterations on the prognosis of thyroid carcinomas, recommendations have to be defined that may lead to individually optimized treatment strategies.
authors.affiliation: Thomas J. Musholt, M.D., Section of Endocrine Surgery, Dept. of General, Visceral- and Transplantation Surgery, University Medicine Mainz, Langenbeckstr. 1, 55131 Mainz, Germany, Tel. +49/(0)61 31/17 71 79, Fax +49/(0)61 31/17 47 71 79, E-mail: musholt@uni-mainz.de.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Musholt
authors.forename: P B
authors.initials: PB
authors.lastname: Musholt
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D044963:Biopsy, Fine-Needle / Q000639:trends*; D019317:Evidence-Based Medicine; D005544:Forecasting; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing / Q000639:trends*; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000639:trends*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013964:Thyroid Neoplasms / Q000235:genetics* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D005819:Genetic Markers
keywords: Thyroid; fine needle aspiration biopsy; molecular genetics